Airway Papillomatosis: New Treatments for an Old Challenge
Authors:
Open Access
- 18 September 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 7, 383
Abstract
Recurrent respiratory papillomatosis (RRP) is the recurrent growth of small, benign tumors, or papillomas, in the respiratory tract, caused by human papillomavirus (HPV). Currently, there is no cure. Palliative treatments seek to prevent airway obstruction, keep underlying tissues healthy, and maintain voice quality. The most common intervention, the local surgical removal of papillomas, may be inadequate as a standalone treatment for pediatric populations that experience rapid papilloma regrowth, as repeated surgeries cause increased damage to the surrounding tissues and impose significant emotional and economic burden on families. Interferon α and Cidofovir have been shown to lengthen the time between surgical interventions and/or decrease the total number of procedures needed, although the evidence of their efficacy and safety is controversial. Novel therapies, including photodynamic therapy, indole-3-carbinol, anti-reflux medication, heat shock protein, and Mumps and HPV vaccination, may provide potential avenues for treatment, but require further research. Among all the novel therapies investigated, systemic bevacizumab seems to offer the most promising alternative to surgery. Randomized control trials to investigate its impact, especially in a pediatric population, should be conducted before implementing it as a standard form of care. This review will summarize the latest literature on medical care for aggressive RRP disease.Keywords
This publication has 39 references indexed in Scilit:
- Bevacizumab i cidofovir w leczeniu HPV-zależnej brodawczakowatości krtani – przegląd literaturyOtolaryngologia Polska, 2018
- Recurrent respiratory papillomatosis: current and future perspectivesTherapeutics and Clinical Risk Management, 2015
- ETIOPATHOGENESIS OF RECURRENT LARYNGEAL PAPILLOMATOSIS AND CONTEMPORARY TREATMENT STRATEGIESActa Medica Medianae, 2014
- Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in ChildrenJAMA Otolaryngology–Head & Neck Surgery, 2013
- Intralesional cidofovir for recurrent respiratory papillomatosis: Systematic review of efficacy and safetyJournal of Laryngology and Voice, 2011
- Cidofovir Efficacy in Recurrent Respiratory Papillomatosis: A Randomized, Double-Blind, Placebo-Controlled StudyAnnals of Otology, Rhinology & Laryngology, 2008
- Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-upAnnals of Otology, Rhinology & Laryngology, 2005
- American Society of Pediatric Otolaryngology Members' Experience With Recurrent Respiratory Papillomatosis and the Use of Adjuvant TherapyJAMA Otolaryngology–Head & Neck Surgery, 2004
- Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report)The Journal of Laryngology & Otology, 2004
- Treatment of Recurrent Respiratory Papillomatosis with Human Leukocyte InterferonNew England Journal of Medicine, 1988